Jean M - Search Results

1

CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.

Haymour L, Jean M, Smulski C, Legembre P. Haymour L, et al. Among authors: jean m. Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189004. doi: 10.1016/j.bbcan.2023.189004. Epub 2023 Oct 20. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37865305 Free article. Review.

2

Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

Kurma K, Boizard-Moracchini A, Galli G, Jean M, Vacher P, Blanco P, Legembre P. Kurma K, et al. Among authors: jean m. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188596. doi: 10.1016/j.bbcan.2021.188596. Epub 2021 Jul 26. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34324950 Free article. Review.

3

CD95 Structure, Aggregation and Cell Signaling.

Levoin N, Jean M, Legembre P. Levoin N, et al. Among authors: jean m. Front Cell Dev Biol. 2020 May 5;8:314. doi: 10.3389/fcell.2020.00314. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32432115 Free PMC article. Review.

4

MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways.

Kenji SF, Kurma K, Collet B, Oblet C, Debure L, Di Primo C, Minder L, Vérité F, Danger Y, Jean M, Penna A, Levoin N, Legembre P. Kenji SF, et al. Among authors: jean m. Cell Death Dis. 2022 Oct 23;13(10):895. doi: 10.1038/s41419-022-05352-0. Cell Death Dis. 2022. PMID: 36274061 Free PMC article.

5

Role of metalloproteases in the CD95 signaling pathways.

Devel L, Guedeney N, Bregant S, Chowdhury A, Jean M, Legembre P. Devel L, et al. Among authors: jean m. Front Immunol. 2022 Dec 5;13:1074099. doi: 10.3389/fimmu.2022.1074099. eCollection 2022. Front Immunol. 2022. PMID: 36544756 Free PMC article. Review.

6

CD95L concatemers highlight different stoichiometries of CD95-mediated apoptotic and nonapoptotic pathways.

Lebrault E, Oblet C, Kurma K, Levoin N, Jeannet R, Jean M, Vacher P, Legembre P. Lebrault E, et al. Among authors: jean m. Eur J Immunol. 2024 Jan;54(1):e2350626. doi: 10.1002/eji.202350626. Epub 2023 Oct 24. Eur J Immunol. 2024. PMID: 37837385 Free article.

7

Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation.

Poissonnier A, Guégan JP, Nguyen HT, Best D, Levoin N, Kozlov G, Gehring K, Pineau R, Jouan F, Morere L, Martin S, Thomas M, Lazaro E, Douchet I, Ducret T, van de Weghe P, Blanco P, Jean M, Vacher P, Legembre P. Poissonnier A, et al. Among authors: jean m. Nat Chem Biol. 2018 Dec;14(12):1079-1089. doi: 10.1038/s41589-018-0162-9. Epub 2018 Nov 14. Nat Chem Biol. 2018. PMID: 30429604

8

Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.

Fouqué A, Jean M, Weghe Pv, Legembre P. Fouqué A, et al. Among authors: jean m. Recent Pat Anticancer Drug Discov. 2016;11(3):283-96. doi: 10.2174/1574892811666160519113731. Recent Pat Anticancer Drug Discov. 2016. PMID: 27194555 Review.

9

Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis.

Nguyen HT, Guégan JP, Poissonnier A, Jouan F, Best D, van de Weghe P, Vacher P, Levoin N, Legembre P, Jean M. Nguyen HT, et al. Among authors: jean m. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2094-2099. doi: 10.1016/j.bmcl.2019.07.006. Epub 2019 Jul 5. Bioorg Med Chem Lett. 2019. PMID: 31301931

10

Investigation of Phospholipase Cγ1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors.

Tripathi N, Vetrivel I, Téletchéa S, Jean M, Legembre P, Laurent AD. Tripathi N, et al. Among authors: jean m. Int J Mol Sci. 2019 Sep 23;20(19):4721. doi: 10.3390/ijms20194721. Int J Mol Sci. 2019. PMID: 31548507 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters